Dimethyl-octadecyl-(2,3,4,5,6-pentahydroxyhexyl)azanium

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Dimethyl-octadecyl-(2,3,4,5,6-pentahydroxyhexyl)azanium
• 化学式: C26H56NO5+
• 分子量: 462.7
• InChiKey: JSMLJHVNWQPILB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  32
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  101
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• NOVEL SURFACTANTS AND FORMULATIONS
  申请人：Lennon Patrick J.

  公开号：US20100234228A1

  公开（公告）日：2010-09-16

  A herbicidal composition is provided comprising an aqueous solution of N-phosphonomethylglycine, predominantly in the form of the potassium salt thereof, at a concentration of at least 300 g a.e./l of the composition; and a surfactant component in solution or stable suspension, emulsion, or dispersion in the water, comprising one or more surfactants in a total amount of about 20 to about 300 g/l of the composition, wherein the composition has a viscosity of less than about 250 centipoise at 0° C. or a Gardner color value less than 10.

  提供了一种除草剂组合物，其包括水溶液中的N-磷酸甲基甘氨酸，主要以其钾盐形式存在，浓度至少为300克/升组合物；以及溶解或稳定悬浮、乳化或分散在水中的表面活性剂组分，包括一种或多种表面活性剂，总量约为20至300克/升组合物，其中该组合物在0℃下的粘度小于约250厘泊或者Gardner色值小于10。
• PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS
  申请人：GLYCOREGIMMUNE, INC.

  公开号：US20160158258A1

  公开（公告）日：2016-06-09

  In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.
• [EN] PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS<br/>[FR] PRÉVENTION ET TRAITEMENT DE PATHOLOGIES INFLAMMATOIRES
  申请人：GLYCOREGIMMUNE INC

  公开号：WO2016094226A1

  公开（公告）日：2016-06-16

  In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.